Primer: PegBio (2565 HK) - Aug 2026
PegBio is a clinical-stage biotechnology company transitioning to commercialization, with its core asset, Visepegenatide (PaidakangĀ®), a...
94 Views
š¼SK or SearchENTITY
PegBio (2565 HK)
PegBio (2565 HK)
36
Analysis
Health Care ā¢ China
PegBio Co., Ltd. is a biotechnology company focused on the discovery and development of innovative therapies for chronic diseases, particularly metabolic disorders. The company develops differentiated therapeutics for conditions such as type 2 diabetes mellitus, obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. PegBio was founded in 2008 and is headquartered in Hangzhou, Zhejiang Province, China.
morex